Modality
Gene Therapy
MOA
BETi
Target
IL-13
Pathway
Incretin
Heart Failure
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
Dec 2023
→ Jul 2031
Phase 2Current
NCT05032053
454 pts·Heart Failure
2023-12→2031-07·Completed
454 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-085.3y awayPh3 Readout· Heart Failure
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Complet…
Catalysts
Ph3 Readout
2031-07-08 · 5.3y away
Heart Failure
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05032053 | Phase 2/3 | Heart Failure | Completed | 454 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| 369-8021 | Hansoh Pharma | Approved | BTK |